Prediction of NEC With Urinary iFABP
Primary Purpose
Prematurity, Necrotizing Enterocolitis
Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Assessment of urinary iFABP
Administration of enteral feedings
Sponsored by
About this trial
This is an interventional diagnostic trial for Prematurity focused on measuring Prematurity, Necrotizing Enterocolitis, Biomarkers, Intestinal Fatty Acid Binding Protein, Feeding
Eligibility Criteria
Inclusion Criteria:
- Gestational age less than 33 weeks
- Admission to Loma Linda University Children's Hospital NICU within 48 hours of life
Exclusion Criteria:
- Anuria
- Congenital gastrointestinal anomaly
Sites / Locations
- Loma Linda University Children's Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
iFABP Monitored
Arm Description
Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
Outcomes
Primary Outcome Measures
Incidence of necrotizing enterocolitis
Secondary Outcome Measures
Time to caloric goal for enteral feedings
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01805206
Brief Title
Prediction of NEC With Urinary iFABP
Official Title
An Assessment of Urinary Intestinal Fatty Acid Binding Protein as a Early Predictor of Necrotizing Enterocolitis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2015
Overall Recruitment Status
Withdrawn
Why Stopped
PI left institution prior to receiving funding
Study Start Date
November 2014 (undefined)
Primary Completion Date
July 2016 (Anticipated)
Study Completion Date
July 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Loma Linda University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
During the first four days of life, intestinal fatty acid binding protein (iFABP) is elevated in the urine of premature babies who go on to develop necrotizing enterocolitis (NEC) days to weeks later. This study aims to determine whether the withholding of feedings in babies with an elevated urinary iFABP can reduce the incidence of NEC.
Detailed Description
Necrotizing enterocolits (NEC) occurs with an incidence of 3-7% in very low birth weight (<1500g) infants and is associated with significant morbidity and mortality. Earlier detection of a subclinical prodrome in NEC might allow for the institution of measures that could prevent or attenuate the severity of disease. We have demonstrated that levels of urinary intestinal fatty acid binding protein (iFABPu), a sensitive and specific marker for intestinal mucosal injury, were elevated in the first 4 days of life in all infants who subsequently developed NEC. We hypothesize that, in the context of an elevated iFABPu in the neonatal period, a significant proportion of NEC cases could be averted by not initiating feedings.
The proposed study will be a three-year prospective trial of iFABPu monitoring during the neonatal period in 220 infants of gestational age less than 33 weeks. Urine will be collected in 12-hour aliquots over the first four days of life and the iFABPu will be measured. On the afternoon of day of life four, infants in whom iFABPu exceeded 1000 pg/ml at any time will be continued with no feedings, iFABPu will continue to be measured, and trophic, breast milk feedings will only be initiated after iFABPu has normalized for five days. Infants with non-elevated iFABPu over the first four days of life will have feedings initiated on day of life four, in the absence of other contraindications. All subjects will have urine collected daily over their entire hospital stay for iFABPu assay. However, after the active study period (after feedings have been initiated) iFABPu findings will not be communicated to the physicians caring for the subjects, but will be evaluated retrospectively in order to better define the utility of iFABPu as a marker for impending NEC later in newborn life.
If iFABPu monitoring is shown to be effective in reducing the incidence of NEC it would revolutionize the care of premature infants by providing physicians with a tool that would permit feeding decisions to be based directly upon the viability of the intestine, rather than intuition.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prematurity, Necrotizing Enterocolitis
Keywords
Prematurity, Necrotizing Enterocolitis, Biomarkers, Intestinal Fatty Acid Binding Protein, Feeding
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
iFABP Monitored
Arm Type
Experimental
Arm Description
Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
Intervention Type
Other
Intervention Name(s)
Assessment of urinary iFABP
Intervention Type
Other
Intervention Name(s)
Administration of enteral feedings
Primary Outcome Measure Information:
Title
Incidence of necrotizing enterocolitis
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Time to caloric goal for enteral feedings
Time Frame
90 days
10. Eligibility
Sex
All
Maximum Age & Unit of Time
2 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Gestational age less than 33 weeks
Admission to Loma Linda University Children's Hospital NICU within 48 hours of life
Exclusion Criteria:
Anuria
Congenital gastrointestinal anomaly
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerald Gollin, MD
Organizational Affiliation
Loma Linda University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Loma Linda University Children's Hospital
City
Loma Linda
State/Province
California
ZIP/Postal Code
92354
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
21238645
Citation
Mannoia K, Boskovic DS, Slater L, Plank MS, Angeles DM, Gollin G. Necrotizing enterocolitis is associated with neonatal intestinal injury. J Pediatr Surg. 2011 Jan;46(1):81-5. doi: 10.1016/j.jpedsurg.2010.09.069.
Results Reference
background
Citation
Stadie D, Boskovic DS, Plank MS, et al. Elevated urinary intestinal fatty acid binding protein precedes clinical indicators of necrotizing enterocolitis. JSR 179:319, 2013.
Results Reference
background
Learn more about this trial
Prediction of NEC With Urinary iFABP
We'll reach out to this number within 24 hrs